Published in AIDS Weekly, October 22nd, 2007
"Third-generation anti-HCV enzyme immunoassays seem to have superior performance compared to second-generation immunoassays in this context....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.